Integrin Receptor Antagonist

Name
Integrin Receptor Antagonist
Accession Number
DBCAT003280  (DBCAT004289)
Description

Not Available

Drugs
DrugDrug Description
NatalizumabA monoclonal anti-integrin antibody used to treat Crohn's disease or multiple sclerosis.
VedolizumabAn integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults.
EtrolizumabA humanized IgG1κ anti-β7 integrin subunit monoclonal antibody under investigation for use in ulcerative colitis and Crohn's disease.
Drugs & Drug Targets
DrugTargetType
NatalizumabIntegrin alpha-4target
NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
NatalizumabIntercellular adhesion molecule 1target
VedolizumabIntegrin alpha-4target
VedolizumabIntegrin beta-7target
EtrolizumabIntegrin beta-7target